Asantae Provides 2011 Review and Update

VANCOUVER, Feb. 29, 2012 /CNW/ - Asantae Holdings International Inc. (TSXV: JVA, OTC PINK: ASNHF) ("Asantae" or the "Company"), a producer and marketer of innovative nutritional products through a network of independent distributors, provided a review of the 2011 accomplishments.

Dan Lundell, Asantae's CEO said, "2011 was a transformative year for Asantae.  Among our numerous accomplishments was the successful development and rollout out of our flagship weight loss product, RealW8™.  We believe that the Company is now positioned for rapid and sustainable growth."

Achievements and Objectives

In the last two quarters of 2011, the Company successfully achieved the following strategic initiatives:

  • Completed final development of and pre-launched RealW8™ in late August.  RealW8™ is our revolutionary new weight loss product that blunts sugar spikes, reduces carb cravings and helps people stay satiated and break the carb addiction cycle.
  • Completed entire corporate rebranding
  • Updated all company literature, brochures, web and marketing collateral
  • Created and deployed new, more lucrative "binary" style compensation plan for Asantae Independent Affiliates which has facilitated increased growth and recruiting
  • Deployed new, more robust business software platform to accommodate growth and enhance the user experience for our Independent Affiliates
  • Grew the ranks of Active Affiliates by over 100% during the pre-launch phase (September - December 2011)
  • Increased operational efficiency by trimming overhead and focused capital expenditures to match new strategic initiatives
  • Restructured management team to implement a new corporate vision and oversee the expected growth in 2012 and beyond

About Asantae

Asantae Holdings International Inc. (www.asantae.com) (TSXV: JVA, OTC PINK: ASNHF) is a producer and marketer of innovative nutritional products through a network of independent distributors (Asantae Independent Affiliates). Asantae's flagship product RealW8™ addresses the primary threat to public health in the industrialized world; overweight and obesity.  Asantae's approach to this threat is based on a body of research related to the brain chemistry of addiction, chronic low-grade inflammation and oxidative stresses which, according to scientific and medical research, are the underlying conditions for most modern epidemic diseases (obesity, heart disease, diabetes, stroke, some cancers, etc.).

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

Certain information in this news release is forward-looking within the meaning of certain securities laws, and is subject to important risks, uncertainties and assumptions. This forward-looking information includes, among other things, information with respect to the Company's beliefs, plans, expectations, anticipations, estimates and intentions, including the listing and trading of the Company's common shares on the Exchange.  The words "may", "could", "should", "would", "suspect", "outlook", "believe", "anticipate", "estimate", "expect", "intend", "plan", "target" and similar words and expressions are used to identify forward-looking information. The forward-looking information in this news release describes the Company's expectations as of the date of this news release.

The results or events anticipated or predicted in such forward-looking information may differ materially from actual results or events. Material factors which could cause actual results or events to differ materially from such forward- looking information include, among others, the Company's ability to develop new products which will receive market acceptance, to receive market acceptance in new markets outside the United States, to engage and retain qualified key personnel, employees and affiliates, to obtain capital and credit and to protect its intellectual property rights.

The Company cautions that the foregoing list of material factors is not exhaustive. When relying on the Company's forward-looking information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. The Company has assumed a certain progression, which may not be realized. It has also assumed that the material factors referred to in the previous paragraph will not cause such forward-looking information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors.

THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS NEWS RELEASE REPRESENTS THE EXPECTATIONS OF THE COMPANY AS OF THE DATE OF THIS NEWS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE. WHILE THE COMPANY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME.

SOURCE Asantae Holdings International, Inc

For further information:

Asantae Holdings International Inc.
Dan Lundell, CEO/COO
danlundell@asantae.com
10153 E Hampton Ave, Ste 101, Mesa, AZ, 85209 USA
Phone: 480-278-8712 / Fax: 480-383-6147

Sequoia Partners Inc.
James Beesley
james@sequoiapartners.ca
Phone: 778-389-7715
or
Adam Rabiner
adamr@sequoiapartners.ca
Phone: 604-868-7881

Profil de l'entreprise

Asantae Holdings International, Inc

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.